Ardelyx has appointed William Bertrand Jr to its board of directors.
Ardelyx is a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases.
Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP and CEO for Salix Pharmaceuticals.
He said: “Ardelyx is uniquely positioned within the life sciences, both in terms of the strength and track record of its senior team, as well as its strategy addressing diseases with substantial unmet needs.”
Mike Raab, president and CEO of Ardelyx, added: “Bill brings extensive experience helping companies growth through early stages of development and into commercialisation.
“His expertise, both operationally and as general counsel, will be of great importance as we continue to accelerate the advancement of our lead programs and develop into a commercial-ready company.”